24 January 2025 - The MHRA has today approved garadacimab (Andembry) for patients aged 12 years and older with hereditary angioedema to prevent angioedema attacks.

This national approval has been granted through an ACCESS work-sharing procedure. The ACCESS consortium is a medium-sized coalition of regulatory authorities that work together to promote greater regulatory collaboration and alignment of regulatory requirements.

Read UK Government press release